InnovHeart Closes Series B Financing of $24 Million

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

InnovHeart s.r.l., a developer of novel Transcatheter Mitral Valve Replacement (TMVR) systems for the treatment of mitral valve disease, announced today the closing of a $23.8 million round of equity financing. Founded in 2015 by Giovanni Righini, a 30-year veteran of the heart valve industry, the company maintains offices outside Milan, Italy, and Boston, Massachusetts.

InnovHeart s.r.l., reports proceeds from the financing will be used to complete the First-in-Human clinical evaluation of the company’s unique Saturn TMVR system using a trans-apical approach.  The round will also allow InnovHeart to finalize the development of the trans-septal delivery system, which uses the same Saturn valve technology.

The Series B round was raised from existing investor Genextra, which has been the sole investor since 2015, and a syndicate led by Panakes Partners, with CDP Venture Capital and Indaco Venture Partners joining the round.

“With millions of patients suffering from severe Mitral Regurgitation, there remains an unmet clinical need for a safer, less-invasive treatment that has the potential to eliminate MR.  With the support of Genextra and our new investors in this Series B financing, we are excited to be able to take the Saturn TMVR into the clinic and begin providing a solution for these patients,” said Keith D. Dawkins MD, Chairman of the InnovHeart Board of Directors and former Executive Vice President and Global Chief Medical Officer at Boston Scientific.

In support of this Series B investment, Barbara Castellano will be joining the InnovHeart Board of Directors to represent Panakes Partners, bringing with her a long background in cardiovascular devices from her experience at Sorin (now LivaNova).

“The innovative design of Saturn TMVR and its unique approach to delivering and anchoring the implant has the potential to provide significant advantages over first-generation systems and the ability to treat a large and heterogeneous patient population,” said Barbara Castellano.

“Genextra is eager to continue supporting InnovHeart through the significant milestones the Company is about to achieve, bringing the novel Saturn valve to trans-apical and trans-septal clinical testing,” said Federica Draghi, Investment Director at Genextra.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.